

National Pharmaceutical Pricing Authority

**Subject: Minutes of the 50<sup>th</sup> meeting of the Multidisciplinary Committee of Experts held on 21.04.2023 at 02:00PM.**

50<sup>th</sup> meeting of the "Multidisciplinary Committee of Experts" was held on 21.04.2023 at 02:00 PM under the convenorship of Shri Manmohan Sachdeva, Advisor (Cost), through video-conferencing. The following members attended the meeting through video conferencing: -

1. Shri A.K. Pradhan, Jt. Drugs Controller, CDSCO
2. Prof. Y. K. Gupta, Principal Scientific Advisor (projects), THSTI-DBT, GoI & Ex-HoD, Pharmacology & Dean (Academics), AIIMS, New Delhi – Co-opted member
3. Dr. Pooja Gupta, Associate Professor, Department of Pharmacology, AIIMS-New Delhi.

The following officers of NPPA attended and presented the cases before the Committee

1. Ms. Rashmi Tahiliani, Jt. Director (Pricing)
2. Shri Mahaveer Saini, Deputy Director (Pricing), NPPA

**Agenda No. 1 - Each film coated tablet contains: Telmisartan IP 40mg + Bisoprolol Fumarate IP 2.5mg for M/s Ravenbhel Healthcare Pvt. Ltd. (Manufacturer) and M/s Emcure Pharmaceuticals Limited (Marketer)**

The Committee deliberated on the agenda item and recommended the retail price of each film coated tablet contains: Telmisartan IP 40mg + Bisoprolol Fumarate IP 2.5mg for M/s Ravenbhel Healthcare Pvt. Ltd. (Manufacturer) and M/s Emcure Pharmaceuticals Limited (Marketer) at Rs. 10.97 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 2.5mg +Telmisartan IP40mg		
(a)	Telmisartan IR 40 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	7.32
(b)	Calculated retail price of Bisoprolol Fumarate IP 2.5mg tablet <b>(Annexure-I)</b>	Retail price (as per July, 2022 data)	4.56
(c)	Retail Price		11.88
(d)	Less 20% of the lower of (a) or (b)		0.91



(e)	Worked out Retail Price (c)-(d)		10.97
(f)	Claimed Retail price		15.00
(g)	Recommended retail price		10.97

**Agenda No. 2 - Each film coated tablet contains: Telmisartan IP 40mg + Bisoprolol Fumarate IP 5mg for M/s Ravenbhel Healthcare Pvt. Ltd. (Manufacturer) and M/s Emcure Pharmaceuticals Limited (Marketer)**

The Committee deliberated on the agenda item and recommended the retail price of each film coated tablet contains: Telmisartan IP 40mg + Bisoprolol Fumarate IP 5mg for M/s Ravenbhel Healthcare Pvt. Ltd. (Manufacturer) and M/s Emcure Pharmaceuticals Limited (Marketer) at Rs. 12.62 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 5 mg +Telmisartan IP40mg		
(a)	Telmisartan IR 40 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	7.32
(b)	Calculated retail price of Bisoprolol Fumarate IP 5 mg tablet(Annexure-II)	Retail price (as per July, 2022 data)	6.62
(c)	Retail Price		13.94
(d)	Less 20% of the lower of (a) or (b)		1.32
(e)	Worked out Retail Price (c)-(d)		12.62
(f)	Claimed Retail price		18.00
(g)	Recommended retail price		12.62

**Agenda No. 3 - Each film coated tablet contains: Telmisartan IP 40mg + Bisoprolol Fumarate IP 2.5mg for M/s Ravenbhel Healthcare Pvt. Ltd. (Manufacturer) and M/s Alembic Pharmaceuticals Ltd. (Marketer)**

The Committee deliberated on the agenda item and recommended the retail price of each film coated tablet contains: Telmisartan IP 40mg + Bisoprolol Fumarate IP 2.5mg for M/s Ravenbhel Healthcare Pvt. Ltd. (Manufacturer) and M/s Alembic Pharmaceuticals Ltd. (Marketer) at Rs. 9.82 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 2.5mg +Telmisartan		

9



	IP40mg		
(a)	Telmisartan IR 40 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	7.32
(b)	Calculated retail price of Bisoprolol Fumarate IP 2.5mg tablet( <b>Annexure-III</b> )	Retail price (as per August, 2022 data)	4.56
(c)	Retail Price		11.88
(d)	Less 20% of the lower of (a) or (b)		0.91
(e)	Worked out Retail Price (c)-(d)		10.97
(f)	Claimed Retail price		9.82
(g)	Recommended retail price		9.82

**Agenda No. 4 - Each film coated tablet contains: Telmisartan IP 40mg + Bisoprolol Fumarate IP 5mg for M/s Ravenbhel Healthcare Pvt. Ltd. (Manufacturer) and M/s Alembic Pharmaceuticals Ltd. (Marketer)**

The Committee deliberated on the agenda item and recommended the retail price of each film coated tablet contains: Telmisartan IP 40mg + Bisoprolol Fumarate IP 5mg for M/s Ravenbhel Healthcare Pvt. Ltd. (Manufacturer) and M/s Alembic Pharmaceuticals Ltd. (Marketer) at Rs. 11.60 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 5 mg +Telmisartan IP40mg		
(a)	Telmisartan IR 40 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	7.32
(b)	Calculated retail price of Bisoprolol Fumarate IP 5 mg tablet( <b>Annexure-IV</b> )	Retail price (as per August, 2022 data)	6.62
(c)	Retail Price		13.94
(d)	Less 20% of the lower of (a) or (b)		1.32
(e)	Worked out Retail Price (c)-(d)		12.62
(f)	Claimed Retail price		11.60
(g)	Recommended retail price		11.60

R

**Agenda No. 5 - Each uncoated bilayered tablet contains: Azelnidipine IP 16mg + Telmisartan IP 40mg for M/s Mascot Health Series Pvt. Ltd. (Manufacturer) and M/s Torrent Pharmaceuticals Limited (Marketer)**

The Committee deliberated on the agenda item and recommended the retail price of each uncoated bilayered tablet contains: Azelnidipine IP 16mg + Telmisartan IP 40mg for M/s Mascot Health Series Pvt. Ltd. (Manufacturer) and M/s Torrent Pharmaceuticals Limited (Marketer) at Rs. 17.96 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each uncoated bilayered tablet contains: Azelnidipine IP 16mg + Telmisartan IP 40mg		
(a)	Telmisartan IR 40 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	7.32
(b)	Calculated retail price of Azelnidipine IP 16mg tablet (Annexure-V)	Retail price (as per August, 2022 data)	12.10
(c)	Retail Price		19.42
(d)	Less 20% of the lower of (a) or (b)		1.46
(e)	Worked out Retail Price (c)-(d)		17.96
(f)	Claimed Retail price		18.50
(g)	Recommended retail price		17.96

**Agenda No. 6 - Each uncoated bilayered tablet contains: Azelnidipine IP 16mg + Telmisartan IP 40mg for M/s Mascot Health Series Pvt. Ltd. (Manufacturer) and M/s Glenmark Pharmaceuticals Limited (Marketer)**

The Committee deliberated on the agenda item and recommended the retail price of each uncoated bilayered tablet contains: Azelnidipine IP 16mg + Telmisartan IP 40mg for M/s Mascot Health Series Pvt. Ltd. (Manufacturer) and M/s Glenmark Pharmaceuticals Limited (Marketer) at Rs. 17.82 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each uncoated bilayered tablet contains: Azelnidipine IP 16mg + Telmisartan IP 40mg		
(a)	Telmisartan IR 40 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	7.32

Q



(b)	Calculated retail price of Azelnidipine IP 16 mg tablet( <b>Annexure-VI</b> )	Retail price (as per July, 2022 data)	11.96
(c)	Retail Price		19.28
(d)	Less 20% of the lower of (a) or (b)		1.46
(e)	Worked out Retail Price (c)-(d)		17.82
(f)	Claimed Retail price		19.19
(g)	Recommended retail price		17.82

**Agenda No. 7 - Each uncoated tablet contains: Paracetamol IP 500mg + Caffeine IP 50 mg for M/s Troikaa Pharmaceuticals Limited (Manufacturer and Marketer)**

The Committee deliberated on the agenda item and recommended the retail price of each uncoated tablet contains: Paracetamol IP 500mg + Caffeine IP 50 mg for M/s Troikaa Pharmaceuticals Limited (Manufacturer and Marketer) at Rs. 1.77 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each uncoated tablet contains: Paracetamol IP 500mg + Caffeine IP 50mg		
(a)	Paracetamol IP 650mg + Caffeine IP 50 Mg <b>(Annexure-VII)</b>	Retail price (as per August, 2022 data)	3.10
(b)	Present applicable ceiling price of Paracetamol IP 650 mg tablet	Ceiling price (vide SO. No. 1499(E) dated 30.03.2022)	2.04
(c)	Derived price of caffeine IP 50 mg tablet(a-b)		1.06
(d)	Present applicable ceiling price of Paracetamol IP 500 mg tablet	Ceiling price (vide SO. No. 1499(E) dated 30.03.2022)	1.01
(e)	Worked out Retail Price (c)+(d)		2.07
(f)	Claimed Retail price		1.77
(g)	Recommended retail price		1.77

**Agenda No. 8 - Each film coated tablet contains: Bempedoic Acid 180mg + Atorvastatin Calcium IP eq. to Atorvastatin 80mg for M/s Exemed Pharmaceuticals (Manufacturer) and M/s Eris Lifesciences Limited (Marketer)**

*R*

The Committee deliberated on the agenda item and recommended the retail price of each film coated tablet contains: Bempedoic Acid 180mg + Atorvastatin Calcium IP eq. to Atorvastatin 80mg for M/s Exemed Pharmaceuticals (Manufacturer) and M/s Eris Lifesciences Limited (Marketer) at Rs. 52.97 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated tablet containing Atorvastatin Calcium IP eq. to Atorvastatin 80mg and Bempedoic Acid 180mg		
(a)	Derived retail price of Atorvastatin 80 mg tablet( <b>Note-I</b> )	Retail price (as per the formula of Pranob Sen Committee)	38.55
(b)	Calculated retail price of Atorvastatin 80mg tablet <b>(Annexure-VIII A)</b>	Retail price (as per Pharmatrac data for the period Sep., 2021 to August, 2022 is taken and Pharmatrac database month is March, 2023)	36.39
(c)	(a) or (b), whichever is lower		36.39
(d)	Calculated retail price of Bempedoic Acid 180 mg tablet <b>(Annexure-VIII B)</b>	Retail price (as per Pharmatrac data for the period Sep., 2021 to August, 2022 is taken and Pharmatrac database month is March, 2023)	20.72
(e)	Retail Price (c+d)		57.11
(f)	Less 20%.of the lower of (c) or (d)		4.14
(g)	Worked out Retail Price (d)-(e)		52.97
(h)	Claimed Retail price		58.03
(j)	Recommended retail price		52.97

**Note-I:** The retail price of Atorvastatin Calcium IP eq. to Atorvastatin 80mg has been attempted as per the formula recommended in the Pronab Sen Committee report. The calculation is as below: -

Derived retail price as per recommendation of Pronab Sen committee:

$$P(s) = P^*[1+a.\{(s-s^*)/s^*\}]$$

Where: P(s) =Price ceiling of the strength s

P\* = price ceiling for reference strength s\*

s = strength in terms of API content

R



s\* = reference strength

a= 0.8 for tablet / capsule and 0.7 for injectibles.

Ceiling price of Atorvastatin 40 mg tablet as on April, 2022 = Rs. 21.42 per tablet excluding GST [S.O. No. 1499(E) dated 30.03.2022]

Derived price of Atorvastatin 80mg tablet after applying the formula of Pronab Sen Committee on the price as per (a) above  
=  $21.42[1+0.80\{80-40/40\}]$  = Rs.38.55 per tablet excluding GST

**Agenda No. 9 - Application by M/s Troikaa Pharmaceuticals Limited for exemption from the provisions of Drug Price Control Order 2013 under Para 32 (i) to (iii) for the formulations "Paracetamol Injection (Intramuscular) 250mg/ml".**

1. The matter relates to exemption under Para 32 (i) to (iii) for the formulations "Paracetamol Injection (Intramuscular) 250mg/ml" applied by M/s Troikaa Pharmaceuticals Limited vide e-mail dated 01.10.2022. The applicant vide letter dated 10.11.2022 submitted the copy of Patent issued by the Patent Office under Indian Patent Act, 1970 dated 09.11.2022 for "Novel Composition comprising Paracetamol and process for preparing the same" bearing registration no. 411067 along with the claim filed with Patent Office (Application No. 630/MUM/2010) dated 09.10.2010.
2. The committee recalled that the matter was deliberated in the 47th meeting of MDC held on 02.12.2022 and committee decided to seek confirmation from Patent office, whether the formulation for which exemption is sought is covered under the Patent granted to M/s Troikaa Pharmaceuticals Limited. In this regard, a letter was sent to Patent Office on 15.12.2022. Patent office vide their email dated 08.03.2023 submitted a report titled as " Report on the scope of claims as granted in Patent No. 411067 (Application No. 630/MUM/2010) pursuant to an application by M/s Troikaa Pharmaceuticals Ltd. made before NPPA for exemption under Para 32 (i) to (iii) of DPCO, 2013 for a formulation "Paracetamol Injection (Instramuscular) 250mg/ml". The report reads as below:

**"Claims in patent as granted:**

*The granted claims (1-15) of Patent No. 411067 (Application No. 630/MUM/2010) are related to "A high concentration parenteral composition of paracetamol delivering full therapeutic dose of 500 mg paracetamol in 2-3 ml in an aqueous, stable, and clear solvent system, wherein the solvent system comprises 25 to 42% u/ glycofurol, greater than 10 up to 37% v/~ ethanol, water, and optionally polyethylene glycol; wherein the concentration of paracetamol is from 166 mg to 250 mg/ml and the composition has a viscosity in a range of 7-28 CPS at 25°C."*

**Comments/inputs on scope of claims in patent:**

From the above granted claims in Patent No. 411067, it can be seen that the formulation " Paracetamol Injection (Instramuscular) 250mg/ml' as applied before NPPA by M/s Troikaa Pharmaceuticals Ltd. for the exemption under Para 32 (i) to (iii) of DPCO, 2013 (as per NPPA's letter dated 15.12.2022

without any other documents, except patent certificate, relating to the Troika's application) falls within the scope of claims as granted in above said patent.

Hence, NPPA may appropriately decide the application as filed by M/s Troikaa Pharmaceuticals Ltd. for the exemption under Para 32 (j) to (in) of DPCO, 2013 for the formulation "Paracetamol Injection (Intramuscular) 250mg/ml" vis-à-vis the granted claims in the above said patent and applicant's submissions, if any, therefor."

3. In this regard, the committee observed that provisions of paragraph 32 of DPCO, 2013 states that:

*Para 32. Non – application of the provisions of this order in certain cases: -*

*The provisions of this order shall not apply to-*

*"(i) a manufacturer producing a new drug patented under the Indian Patent Act, 1970 (39 of 1970), for a period of five years from the date of commencement of its commercial marketing by the manufacturer in the country.";*

*(ii) a manufacturer producing a new drug in the country by a new process developed through indigenous Research and Development and patented under the Indian Patent Act, 1970 (39 of 1970) (process patent) for a period of five years from the date of the commencement of its commercial production in the country.*

*(iii) a manufacturer producing a new drug involving a new delivery system developed through indigenous Research and Development for a period of five years from the date of its market approval in India:*

*Provided that the provision of this paragraph shall apply only when a document showing approval of such new drugs from Drugs Controller General (India) is produced before the Government.*

*Explanation: - Notwithstanding anything contained in this Order, for the purpose of this paragraph "new drug" shall have the same meaning as is assigned to under rule 122E of the Drugs and Cosmetic rules, 1945*

4. The committee further observed:
- a. Paracetamol is covered under Schedule-I of DPCO, 2013 and Paracetamol injection 150mg/ml is scheduled formulation. The applicant has applied for exemption of Paracetamol Injection (intramuscular) 250mg/ml.
  - b. Applicant has also submitted the Patent Status of this drugs in other 76 Countries also.
  - c. In the application to the Patent office, the claim was made for 'the high concentration parenteral composition of paracetamol delivering full therapeutic dose of 500mg Paracetamol in 2-3 ml in an aqueous, stable, and clear solvent system, wherein the composition contains paracetamol in a concentration from 200 to 250mg/ml in a solvent system.
  - d. As per Patent certificate, patent is granted for "Novel Composition comprising Paracetamol and process for preparing the same".
  - e. Applicant has submitted DCGI approval No. MF/FF/SND/36/2022 dated 16.09.2022 for 'Paracetamol Injection Intramuscular, 2ml and each ml contains Paracetamol 250mg, Absolute Alcohol IP 30% v/v, Water for injection IP q.s.'

*R*



- f. State Licensing permission also granted on 26.09.2022 for the formulation as stated in DCGI approval.
5. The committee deliberated upon the matter and upon the report of the Patent office in detail and observed that M/s Troikaa Pharmaceuticals Ltd. fulfils the conditions of para 32(i) of DPCO, 2013 with respect to the formulation "Paracetamol Injection (Intramuscular) 250mg/ml". Accordingly, the committee recommended that exemption may be granted to M/s Troikaa Pharmaceuticals Ltd. under para 32(i) of DPCO, 2013 with respect to the formulation "Paracetamol Injection (Intramuscular) 250mg/ml".

**Agenda No. 10 - Application by M/s Promea Therapeutics for extension of Ceiling Prices of I.V. Fluids with packaging in non-glass with special features in line with S.O. 1569(E), 1570(E), 1571(E), 1574(E), 1576(E), 1577(E) dated 31.03.2023.**

1. The matter relates to application filled by M/s Promea Therapeutics for extension of Ceiling Prices of I.V. Fluids with packaging in non-glass with special features in line with S.O. 1569(E), 1570(E), 1571(E), 1574(E), 1576(E), 1577(E) dated 31.03.2023. In this regard, it is also stated that the applicant has first filed their application vide letter dated 16.12.2022 for three formulations (i) Dextrose Injection IP (5% w/v) in 500ml/LDPE Bottle, (ii) Sodium Chloride & Dextrose Injection IP (0.9% & 5% w/v) in 500ml/LDPE Bottle and (iii) Sodium Chloride Injection IP (0.9% w/v) in 500ml/LDPE Bottle.
2. The applicant vide their letter dated 03.04.2023 stated that they have developed infrastructure for manufacturing I.V. Fluids with packaging in non-glass with special features. The company vide letter dated 03.04.2023 applied for separate ceiling prices of 9 formulations i.e. (i) Dextrose Injection IP (5% w/v) in 500ml/LDPE Bottle, (ii) Sodium Chloride & Dextrose Injection IP (0.9% & 5% w/v) in 500ml/LDPE Bottle, (iii) Sodium Chloride Injection IP (0.9% w/v) in 500ml/LDPE Bottle, (iv) Dextrose Injection IP (25% w/v) in 100ml/LDPE Bottle, (v) Ciprofloxacin Injection IP in 100ml/LDPE Bottle, (vi) Sodium Chloride Injection IP (0.9% w/v) in 100ml/LDPE Bottle, (vii) Ringer Lactate Injection IP in 500ml/LDPE Bottle, (viii) Fluconazole Injection in 100ml/LDPE Bottle and (ix) Metronidazole Injection IP 0.5% in 100ml/LDPE Bottle.
3. The applicant has also claimed that they have also obtained manufacturing permission from State Drug Authority/Central Drug Authority for the same. Their products have special features as "1. Self-Collapsibility and Self Seal ability, 2. Non having Air vent and 3. Having no chance of contamination during manufacture/infusion/admixing level. Applicant has further requested a suitable date to demonstrate their products before multi disciplinary committee of experts in support of their claim.
4. The committee deliberated on the matter and decided that the matter of separate price approval on account special packaging may be taken up after refixation of ceiling price under NLEM 2022 under Revised Schedule-I of DPCO, 2013.
5. Committee also noted separate ceiling prices for Metronidazole Injection IP 0.5% in 100ml/LDPE Bottle has been notified under NLEM, 2022. Therefore, the applicant may be asked to demonstrate their product in the next meeting of MDC.

**Agenda No. 11 - Application by M/s Pureto Life Sciences Private Limited for extension of Ceiling Prices of I.V. Fluids Sodium Chloride 0.9% in 100ML packing with packaging in non-glass with special features (Euro Head).**

1. The matter relates to application filled by M/s Pureto Life Sciences Private Limited for extension of Ceiling Prices of I.V. Fluids Sodium Chloride 0.9% in 100ML packing with packaging in non-glass with special features (Euro Head).



The applicant vide their letter dated 29.10.2022 stated that they have developed infrastructure for manufacturing I.V. Fluids with packaging in non-glass with special features - EURO Head. They have also obtained manufacturing permission from State Drug Authority/Central Drug Authority for the same. Our products have special features as "1. Self Collapsibility and Self Seal Ability, 2. Not having Air vent and 3. Having no chance of contamination during manufacture/infusion/admixing level.

2. The committee deliberated on the matter and decided that the matter of separate price approval on account special packaging may be taken up after re-fixation of ceiling price of the formulation under Revised Schedule-I of DPCO, 2013 (NLEM 2022).

**Agenda No. 12 - Application by M/s Sachin Parenterals Ltd for Price approval of (i) Dextrose Injection IP (5% w/v) 250ml and (ii) Glucose 5% with sodium chloride 0.9% w/v 250ml having special features- Euro Head bottle.**

1. The matter was discussed in various meetings of Multidisciplinary Committee of Experts. As per the deliberations held in 45th meeting of the Multidisciplinary Committee of Experts held on 13.09.2022, separate ceiling prices was recommended. The recommendation of MDC was placed in 102<sup>nd</sup> meeting of the Authority held on 27.09.2022 in which the Authority noted that the separate price as recommended for these IV fluids are not in line with the special ceiling price provided to other strength/ pack size of IV fluids and decided that the matter be referred to the Committee for re-examination.
2. Committee in its 46<sup>th</sup> meeting held on 20.10.2022 noted the decision of the Authority and after deliberation decided that the detailed examination based on Authority's observation be placed in next meeting of the Multidisciplinary Committee of Experts.
3. In 47<sup>th</sup> meeting held on 02.12.2022 the committee decided that the matter of separate price approval on account special packaging may be taken up after re-fixation of ceiling price of the formulation under Revised Schedule-I of DPCO, 2013 (NLEM 2022).
4. The committee deliberated on the matter again and reiterated its decision that the matter of separate price approval on account special packaging may be taken up after re-fixation of ceiling price of the formulation under Revised Schedule-I of DPCO, 2013 (NLEM 2022).

**Agenda No. 13 - Application for "Special Feature rate" for scheduled products (i) Tazofic Injection 2.25 gm containing Piperacillin 2gm + Tazobactam 250mg and (ii) Tazofic Injection 4.5gm containing Piperacillin 4gm Tazobactam 500 mg under Para 11(3) of DPCO 2013.**

1. The matter was discussed in various meetings of Multidisciplinary Committee of Experts. As per the deliberations held in 45<sup>th</sup> meeting of the Multidisciplinary Committee of Experts held on 13.09.2022, additional 15 percent price over the present applicable ceiling price of the formulation for incremental innovation of the packaging was recommended.
2. M/s Gufic Biosciences Ltd made representation on the recommendation made by the Multidisciplinary Committee of Experts vide letter dated 23.09.2022. The matter was also placed before the Authority in its 102<sup>nd</sup> meeting held on 27.09.2022 in which the Authority decided that the representation of the company be referred to the Committee for examination.

92



3. Committee in its 46<sup>th</sup> meeting held on 20.10.2022 noted the representation of the company and after deliberation decided that the company may be asked to submit the additional literature to substantiate their claim and also to make presentation in the next meeting of the committee.
4. In view of above, letter was sent to M/s Gufic Biosciences Ltd on 27.10.2022 requesting to submit the additional literature to substantiate their claim and also to make presentation in the next meeting of the committee. Further, the matter was also deliberated in 47<sup>th</sup> meeting of MDC held on 02.12.2022, wherein it was decided that the matter of separate price approval on account special packaging may be taken up after notification of ceiling price of the formulation under Revised Schedule-I of DPCO, 2013 (NLEM 2022).
5. The committee noted that the ceiling price for the FDC of 'Piperacillin +Tazobactam' has been notified by NPPA vide S.O. No. 87(E) dated 06.01.2023 under NLEM, 2022. Further, the committee also noted that applicant i.e. M/s Gufic Biosciences Ltd has not submitted the additional literature to substantiate their claim as per NPPA's letter dated 27.10.2022. Therefore, after deliberations the committee recommended to reject the application of separate ceiling price of M/s Gufic Biosciences Ltd.

**Agenda No. 14 - Retail price fixation under DPCO, 2013- Each ml contains Ibuprofen IP 100mg for M/s Akums Drugs & Pharmaceuticals (manufacturer) and M/s Cipla Ltd. (marketer).**

1. The matter related to the retail price fixation of Each ml contains Ibuprofen IP 100mg for M/s Akums Drugs & Pharmaceuticals (manufacturer) and M/s Cipla Ltd. (marketer). The matter was deliberated in the 48<sup>th</sup> meeting of MDC held on 20.01.2023, wherein committee recommended as follows:

"10.1. The Committee deliberated on the agenda item and recommended the retail price of each ml contains Ibuprofen IP 100mg for M/s Akums Drugs & Pharmaceuticals (manufacturer) and M/s Cipla Ltd. (marketer) at Rs.5.05 per ml excluding GST as below.

S. No.	Particulars	Amount (Rs.)
(a)	Worked out Retail Price	5.05per ml
(b)	Claimed Retail price	26.78 per ml (Excluding GST)
(c)	Recommended retail price	5.05 per ml

Note 1:

Derived retail price as per recommendation of Pronab Sen committee:

$$P(s) = P^*[1+a.\{(s-s^*)/s^*\}]$$

Where: P(s) = Price ceiling of the strength

P\* = price ceiling for reference strength

s = strength in terms of API content

s\* = reference strength

a= 0.8 for tablet / capsule and 0.7 for injectables.

2



The committee noted that data of Ibuprofen 100mg Injection is not available in the Pharmatrac database. The committee deliberated upon the matter that Diclofenac and Ibuprofen comes under same Section in NLEM 2022 i.e. "*Section 2 Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders.*" and ceiling price of Diclofenac 25mg/ml was already fixed under Scheduled I of DPCO,2013.

Accordingly, the committee recommended as below by applying the Pronab Sen formula to Diclofenac Injection:

The Ceiling Price [SO. 1499(E) dated 30.03.2022] of Diclofenac Injection 25 mg/ml = Rs. 1.63.

Derived retail price of Diclofenac Injection 100 mg/ml as on April, 2022 after applying the formula of Pronab Sen Committee on the price as per (a) above =  $1.63[1+0.7\{(100-25)/25\}] = \text{Rs.}5.05$  (excluding GST)

The same is extended to Ibuprofen IP 100mg/ml."

2. The committee noted that, M/s Cipla Limited had filed representation dated 07.02.2023 stating that the drug with same dosage & strength is imported and sold by one company at prices almost double (Rs. 30 per ML claimed by M/s Cipla and Rs. 74.375 per ML of other company referred by M/s Cipla) of what applicant has claimed. Applicant also stated that there are no other manufacturers of the said formulation and notifying retail price suggested by MDC would lead to discouragement of launches of innovative drugs in India. Therefore, applicant had requested to fix retail price in line with the market available formulation or as claimed by the company.
3. The committee recalled that the matter was again deliberated in the 49<sup>th</sup> meeting of MDC held on 23.02.2023, wherein committee had directed to collect the data from companies (suggested by M/s Cipla Limited and also identified from Websources) and Hospitals/Institutions in this respect and then resubmit the matter to MDC. In view of this, letters sent to two companies i.e. Sandor Medicaids Private Limited (suggested by M/s Cipla Limited) and i.e. SG Pharma Private also (identified from Websources Limited) and 10 Hospitals (Dr. Baba Saheb Ambedkar, Dr. RML, AIIMS Delhi, Amrita Hospital, Lok Nayak Hospital, G.B. Pant, Deen Dayal Upadhyay Hospital, Fortis Healthcare, Apollo and Max) seeking data for the period May 2021 to April 2022 as per provisions of DPCO, 2013.
4. In the above matter, Amrita Hospital, AIIMS Delhi, Apollo Hospital and Fortis Healthcare Gurugram have informed that they have not procured Ibuprofen Injection 100mg/ml. Fortis Healthcare Gurugram has informed that they have procured Ibuprofen Infusion 400mg/100ml. Only one company i.e. Sandor Medicaids Private Limited has submitted the data vide their email dated 10.04.2023.
5. The committee deliberated on the data received from the hospital and the companies and recommended to examine the launch of Ibuprofen

Injection/Infusion by M/s Cipla Limited, M/s Hetero Healthcare Limited and M/s Sandor Medicaids Private Limited without price approval from NPPA for retail price of new drug as per DPCO, 2013.

6. The committee also stated that the applicant i.e. M/s Cipla Limited may be asked to respond particularly on the following:
- (a) Is there any therapeutic advantage of giving Ibuprofen Injection vis-à-vis Diclofenac Injection in terms of efficacy, safety or any other terms?
  - (b) If the equivalent dose of Diclofenac Injection and Ibuprofen Injection are used in any therapeutic indication, then what will be the cost of treatment if (i) Diclofenac Injection used; (ii) Ibuprofen Injection used.

The meeting ended with a vote of thanks to all.

*Rashmi*  
*26/4/23*  
**(RashmiTahiliani)**  
Jt. Director (Pricing)

Copy to:  
All members of the Committee.

Computation of Retail Price based on July, 2022 Data under Para 5 of DPCO, 2013

Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 2.5 mg	Number of Companies consisting of Market Share of 1% & Above		7
	Sum of MAT value considered for price calculation (In Lakhs)		9,366.49
	Sum of PTR per unit considered for price calculation		31.41
	Number of Packs considered		8
	Average PTR		3.93
	Add : 16% Retailer Margin		0.63
	Retail Price (without local taxes)		4.56
	% Reduction with compared to Highest Price		22.49%

Minimum Price (Rs.)	2.43
Maximum Price (Rs.)	5.07
Average of all considered (Rs.)	3.93
Retail Price (Rs.)	4.56

S.No.	Pack Description	BRAND	Company	Strength	Pack Size	Unit	PTR	MAT (Rs.)	M3				
									SKU wise MAT %	100%	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per unit (Rs.) Price Considered
1	BESICOR 2.5 MG TABLET 10	BESICOR	AIANTA PHARMA LTD	2.5 MG	10	TABLET	32.43	17681225	1.87%	1.97%	Y	3.24	3.24
2	BESICOR 2.5 MG TABLET 15	BESICOR	AIANTA PHARMA LTD	2.5 MG	15	TABLET	57.50	898765	0.10%	1.97%	Y	3.83	3.83
3	BESOLOC 2.5 MG TABLET 10	BESOLOC	EAST WEST PHARMA	2.5 MG	10	TABLET	29.29	15612	0.00%	0.00%	N	2.93	
4	BIBETA 2.5 MG TABLET 10	BIBETA	OPISICARE LIFESCENCE PVT LTD	2.5 MG	10	TABLET	35.71	281359	0.03%	0.03%	N	3.57	
5	BISELECT 2.5 MG TABLET 10	BISELECT	INTAS PHARMACEUTICALS LTD	2.5 MG	10	TABLET	24.29	10392688	1.10%	1.10%	Y	2.43	2.43
6	BISOACE 2.5 MG TABLET 10	BISOACE	MOREPEN LABORATORIES LIMITED	2.5 MG	10	TABLET	6.00	13074	0.00%	0.00%	N	0.60	
7	BISOBIS 2.5 MG TABLET 10	BISOBIS	CORONA	2.5 MG	10	TABLET	28.57	1354161	0.14%	0.14%	N	2.86	
8	BISOCAR 2.5 MG TABLET 10	BISOCAR	RUSAN HEALTHCARE PVT. LTD	2.5 MG	10	TABLET	18.70	5479	0.00%	0.00%	N	1.87	
9	BISOHEART 2.5 MG TABLET 10	BISOHEART	MANKIND PHARMACEUTICALS LTD.	2.5 MG	10	TABLET	36.14	59276828	6.27%	6.27%	Y	3.61	3.61
10	BISOLONG 2.5 MG TABLET 10	BISOLONG	MICRO LABS LTD	2.5 MG	10	TABLET	35.00	1527515	0.16%	0.16%	N	3.50	
11	BISONEXT 2.5 MG TABLET 15	BISONEXT	LUPIN LTD	2.5 MG	15	TABLET	68.86	33962857	3.59%	3.59%	Y	4.59	4.59
12	BISOSAFE 2.5 MG TABLET 10	BISOSAFE	ABBOTT HEALTHCARE PVT. LTD	2.5 MG	10	TABLET	39.29	3745044	0.40%	0.40%	N	3.93	
13	BISOTAB 2.5 MG TABLET 10	BISOTAB	JB CHEMICALS	2.5 MG	10	TABLET	49.84	17987741	1.90%	1.90%	Y	4.98	4.98
14	BISVEDA 2.5 MG TABLET 10	BISVEDA	KEPLER HEALTH CARE	2.5 MG	10	TABLET	34.57	1206839	0.13%	0.13%	N	3.46	
15	BIZO 2.5 MG TABLET 10	BIZO	SPECTRA THERAPEUTICS PVT. LTD.	2.5 MG	10	TABLET	30.00	175260	0.02%	0.02%	N	3.00	
16	CONCOR COR 2.5 MG TABLET 10	CONCOR COR	MERCK SPECIALITIES PVT.LTD	2.5 MG	10	TABLET	50.71	684286369	72.41%	72.41%	Y	5.07	5.07
17	CONCOVAS 2.5 MG TABLET 10	CONCOVAS	VASU ORGANICS PVT.LTD	2.5 MG	10	TABLET	47.57	8495.88	0.00%	0.00%	N	4.76	
18	CORBIS 2.5 MG TABLET 15	CORBIS	TORRENT PHARMACEUTICALS LTD.	2.5 MG	15	TABLET	54.93	112163009.5	11.87%	11.87%	Y	3.66	3.66
		Rs. Per Tablet.											
	Worked out Retail Price		4.56	Excluding GST									



Computation of Retail Price based on July, 2022 Data under Para 5 of DPCO, 2013

Number of Companies consisting of Market Share of 1% & Above			6		
Sum of MAT value considered for price calculation (in Lakhs)			11,694.07		
Sum of PTR per unit considered for price calculation			34.28		
Number of Packs considered			6		
Average PTR			5.71		
Add: 1.6% Retailer Margin			0.91		
Retail Price (without local taxes)			6.62		
% Reduction with compared to Highest Price			24.57%		

Each uncoated bilayered tablet contains: Bisoprolol Fumarate, IP 5 mg

Minimum Price (Rs.)	3.04
Maximum Price (Rs.)	7.57
Average of all considered (Rs.)	5.71
Retail Price (Rs.)	6.62

S.No.	पैक विवरण Pack Description	ब्रांड BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR	MAT(Rs.)	100%	Qualify (Y/N) Y=Yes N=No	Price per unit (Rs.)	Price per unit (Rs.) Considered
									SKU wise MAT %			
1	ACBISO 5 MG TABLET 10	ACBISO	ACMEDIX PHARMA LLP	5 MG	10	TABLET	20.71	167316	0.01%	N	2.07	
2	BESICOR 5 MG TABLET 10	BESICOR	AJANTA PHARMA LTD	5 MG	10	TABLET	48.21	3777157	0.32%	N	4.82	
3	BESICOR 5 MG TABLET 15	BESICOR	AJANTA PHARMA LTD	5 MG	15	TABLET	78.57	1290434	0.11%	N	5.24	
4	BIBETA 5 MG TABLET 10	BIBETA	OPISICARE LIFESCIENCE PVT LTD	5 MG	10	TABLET	42.86	329165	0.03%	N	4.29	
5	BISELECT 5 MG TABLET 10	BISELECT	INTAS PHARMACEUTICALS LTD	5 MG	10	TABLET	30.36	12560490	1.05%	Y	3.04	3.04
6	BISOACE 5 MG TABLET 10	BISOACE	MOREPEN LABORATORIES LIMITED	5 MG	10	TABLET	8.77	20881	0.00%	N	-0.88	
7	BISOBIS 5 MG TABLET 10	BISOBIS	CORONA	5 MG	10	TABLET	28.57	1680373	0.14%	N	2.86	
8	BISOCAR 5 MG TABLET 10	BISOCAR	RUSAN HEALTHCARE PVT. LTD	5 MG	10	TABLET	27.14	1818	0.00%	N	2.71	
9	BISOHEART 5 MG TABLET 10	BISOHEART	MANKIND PHARMACEUTICALS, LTD.	5 MG	10	TABLET	56.89	89665865	7.50%	Y	5.69	5.69
10	BISOLONG 5 MG TABLET 10	BISOLONG	MICRO LABS LTD	5 MG	10	TABLET	46.43	3553845	0.30%	N	4.64	
11	BISONEXT 5 MG TABLET 15	BISONEXT	LUPIN LTD	5 MG	15	TABLET	93.29	43233930	3.61%	Y	6.22	6.22
12	BISOSAFE 5 MG TABLET 10	BISOSAFE	ABBOTT HEALTHCARE PVT. LTD	5 MG	10	TABLET	60.49	6979315	0.58%	N	6.05	
13	BISOTAB 5 MG TABLET 10	BISOTAB	JB CHEMICALS	5 MG	10	TABLET	73.58	23766684	1.99%	Y	7.36	7.36
14	BISVEDA 5 MG TABLET 10	BISVEDA	KEPLER HEALTH CARE	5 MG	10	TABLET	47.54	2658342	0.22%	N	4.75	
15	BIZO 5 MG TABLET 10	BIZO	SPECTRA THERAPEUTICS PVT. LTD.	5 MG	10	TABLET	35.72	371809	0.03%	N	3.57	
16	CONCOR 5 MG TABLET 10	CONCOR	MERCK SPECIALITIES PVT.LTD	5 MG	10	TABLET	75.68	858054763	71.72%	Y	7.57	7.57
17	CONCOVAS 5 MG TABLET 10	CONCOVAS	VASU ORGANICS PVT.LTD	5 MG	10	TABLET	56.57	34904	0.00%	N	5.66	
18	CORBIS 5 MG TABLET 15	CORBIS	TORRENT PHARMACEUTICALS LTD.	5 MG	15	TABLET	66.07	142125525.7	11.88%	Y	4.40	4.40
19	ZABESTA 5 MG TABLET 10	ZABESTA	USV PVT LTD	5 MG	10	TABLET	49.43	6042965.79	0.51%	N	4.94	
		Rs. Per Tablet										
	Worked out Retail Price		6.62 Excluding GST									

Annexure-II







5

Computation of Retail Price based on August, 2022 Data under Para 5 of DPCO, 2013

Number of Companies consisting of Market Share of 1% & Above	7
Sum of MAT value considered for price calculation (in Lakhs)	1,404.42
Sum of PTR per unit considered for price calculation	73.00
Number of Packs considered	7
Average PTR	10.43
Add : 16% Retailer Margin	1.67
Retail Price (without local taxes)	12.10
% Reduction with compared to Highest Price	13.08%

Each uncoated bilayered tablet contains: Azelnicipine IP 16 mg

Minimum Price (Rs.)	9.29
Maximum Price (Rs.)	12.00
Average of all considered (Rs.)	10.43
Retail Price (Rs.)	12.1

S.No.	पैक विवरण Pack Description	ब्रांड BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR	14.08.06,936 MAT(Rs.)	100% SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per unit (Rs.)	Price per unit (Rs.) Considered
1.	AZELDIP 16 MG TABLET 10	AZELDIP	GLENMARK PHARMACEUTICALS LTD.	16 MG	10	TABLET	109.29	2485840	1.77%	1.77%	Y	10.93	10.93
2.	AZELIREN 16 MG TABLET 10	AZELIREN	LA RENON	16 MG	10	TABLET	110.00	1880090	1.34%	1.34%	Y	11.00	11.00
3.	AZILTA 16 MG TABLET 10	AZILTA	RPG LIFE SCIENCES LTD.	16 MG	10	TABLET	100.00	280900	0.20%	0.20%	N	10.00	
4.	AZOVAS 16 MG TABLET 10	AZOVAS	JB CHEMICALS	16 MG	10	TABLET	94.25	10417562	7.40%	7.40%	Y	9.43	9.43
5.	AZUSA 16 MG TABLET 10	AZUSA	AJANTA PHARMA LTD	16 MG	10	TABLET	102.14	25107454	17.83%	17.83%	Y	10.21	10.21
6.	CORAZEL 16 MG TABLET 10	CORAZEL	FUSION HEALTHCARE PVT LTD	16 MG	10	TABLET	99.29	84496	0.06%	0.06%	N	9.93	
7.	EMDIP 16 MG TABLET 10	EMDIP	EMCURE PHARMACEUTICALS LTD	16 MG	10	TABLET	92.86	5702718	4.05%	4.05%	Y	9.29	9.29
8.	UNIАЗ 16 MG TABLET 10	UNIАЗ	TORRENT PHARMACEUTICALS LTD.	16 MG	10	TABLET	120.04	64361794	45.71%	45.71%	Y	12.00	12.00
9.	ZEBLONG 16 MG TABLET 10	ZEBLONG	IPCA LABORATORIES PVT LTD.	16 MG	10	TABLET	101.42	30486081	21.65%	21.65%	Y	10.14	10.14
		Rs. Per Tablet											
	Worked out Retail Price		12.10	Excluding GST									

Annexure-2

16

Computation of Retail Price based on July, 2022 Data under Para 5 of DPCO, 2013

Each uncoated bilayered tablet contains: Azelnidipine IP 16 mg		Number of Companies consisting of Market Share of 1% & Above		7
		Sum of MAT value considered for price calculation (in Lakhs)		1,363.89
		Sum of PTR per unit considered for price calculation		72.15
		Number of Packs considered		7
		Average PTR		10.31
		Add: 16% Retailer Margin		1.65
		Retail Price (without local taxes)		11.96
		% Reduction with compared to Highest Price		14.08%

Minimum Price (Rs.)	9.29
Maximum Price (Rs.)	12.00
Average of all considered (Rs.)	10.31
Retail Price (Rs.)	11.96

S.No.	पैक विवरण Pack Description	ब्रांड BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR	100%		Qualify (Y/N) Y=Yes N=No.	Price per unit (Rs.)	Price per unit (Rs.) Considered
								SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)			
1	AZELDIP 16 MG TABLET 10	AZELDIP	GLENMARK PHARMACEUTICALS LTD.	16 MG	10	TABLET	109.29	1.89%	1.89%	Y	10.93	10.93
2	AZELIREN 16 MG TABLET 10	AZELIREN	LA RENON	16 MG	10	TABLET	110.00	1.29%	1.29%	Y	11.00	11.00
3	AZILTA 16 MG TABLET 10	AZILTA	PPG LIFE SCIENCES LTD.	16 MG	10	TABLET	100.00	0.15%	0.15%	N	10.00	
4	AZOVAS 16 MG TABLET 10	AZOVAS	JB CHEMICALS	16 MG	10	TABLET	94.25	7.39%	7.39%	Y	9.43	9.43
5	AZUSA 16 MG TABLET 10	AZUSA	AJANTA PHARMA LTD	16 MG	10	TABLET	93.57	18.21%	18.21%	Y	9.36	9.36
6	CORAZEL 16 MG TABLET 10	CORAZEL	FUSION HEALTHCARE PVT LTD	16 MG	10	TABLET	99.29	0.06%	0.06%	N	9.93	
7	EMDIP 16 MG TABLET 10	EMDIP	EMCLURE PHARMACEUTICALS LTD	16 MG	10	TABLET	92.86	4.65%	4.65%	Y	9.29	9.29
8	UNIАЗ 16 MG TABLET 10	UNIАЗ	TORRENT PHARMACEUTICALS LTD.	16 MG	10	TABLET	120.04	45.32%	45.32%	Y	12.00	12.00
9	ZEBLONG 16 MG TABLET 10	ZEBLONG	IPCA LABORATORIES PVT LTD.	16 MG	10	TABLET	101.42	21.04%	21.04%	Y	10.14	10.14
		Rs. Per Tablet										
	Worked out Retail Price		11.96 Excluding GST									

Annexure-VI







Computation of Retail Price based on August, 2022 Data under Para 5 of DPCO, 2013

Each film coated tablet containing Bempedoic Acid 180mg.	Number of Companies consisting of Market Share of 1% & Above	8
	Sum of MAT value considered for price calculation (in Lakhs)	119.97
	Sum of PTR per unit considered for price calculation	142.84
	Number of Packs considered	8
	Average PTR	17.86
	Add : 16% Retailer Margin	2.86
	Retail Price (without local taxes)	20.72
	% Reduction with compared to Highest Price	21.87%

Minimum Price (Rs.)	17.14
Maximum Price (Rs.)	22.86
Average of all considered (Rs.)	17.86
Retail Price (Rs.)	20.72

S.No.	पैक विवरण Pack Description	ब्रांड BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR	MAT (Rs.)	M3			
									100% SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Quality (Y/N) Y=Yes N=No	Price per unit (Rs.) Considered
1	BELMORE 180 MG TABLET 10	BELMORE	CADILA PHARMACEUTICALS LTD	180 MG	10	TABLET	171.43	190459	1.54%	1.54%	Y	17.14
2	BELRO 180 MG TABLET 10	BELRO	HETERO HEALTHCARE LTD	180 MG	10	TABLET	171.43	20572	0.17%	0.17%	N	17.14
3	BEMDAC 180 MG TABLET 10	BEMDAC	ZYDUS CADILA - ZHL	180 MG	10	TABLET	171.43	3395514	27.52%	27.52%	Y	17.14
4	BEMPALIP 180 MG TABLET 10	BEMPALIP	PULSE PHARMACEUTICALS PVT LTD	180 MG	10	TABLET	170.71	63163	0.51%	0.51%	N	17.07
5	BEMPEDAY 180 MG TABLET 10	BEMPEDAY	ZUVENTUS HEALTHCARE LTD	180 MG	10	TABLET	167.86	105752	0.86%	0.86%	N	16.79
6	BEMPESTA 180 MG TABLET 10	BEMPESTA	TORRENT PHARMACEUTICALS LTD.	180 MG	10	TABLET	171.43	3953862	32.05%	32.05%	Y	17.14
7	BEMPIFY 180 MG TABLET 10	BEMPIFY	LUPIN LTD	180 MG	10	TABLET	171.43	328631	2.66%	2.66%	Y	17.14
8	BEMPOTOL 180 MG TABLET 10	BEMPOTOL	MSN LABORATORIES LTD	180 MG	10	TABLET	178.57	36250	0.29%	0.29%	N	17.86
9	BEMPULESS 180 MG TABLET 10	BEMPULESS	CORONA	180 MG	10	TABLET	171.43	114858	0.93%	0.93%	N	17.14
10	BEPOLY 180 MG TABLET 10	BEPOLY	GLENMARK PHARMACEUTICALS LTD.	180 MG	10	TABLET	171.43	417603	3.38%	3.38%	Y	17.14
11	BRILLO 180 MG TABLET 10	BRILLO	SUN PHARMA LABORATORIES LTD.	180 MG	10	TABLET	171.43	2947225	23.89%	23.89%	Y	17.14
12	DAPCEA 180 MG TABLET 10	DAPCEA	BIOCON LTD	180 MG	10	TABLET	228.57	282513	2.29%	2.29%	Y	22.86
13	EMBIA 180 MG TABLET 10	EMBIA	AJANTA PHARMA LTD	180 MG	10	TABLET	171.43	481375	3.90%	3.90%	Y	17.14
	Worked out Retail Price											
		Rs. Per Tablet										
			20.72	Excluding GST								

Annexure VIII B.